查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2130485

全球藥品定價分析市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Drug Pricing Analytics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 246 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球藥品定價分析市場預計將從2025年的16.3億美元成長至2034年的47億美元，2026年至2034年的複合年成長率（CAGR）為12.49%。隨著製藥公司、醫療服務提供者、保險公司和政府越來越需要數據驅動型工具來了解藥品定價和報銷情況，該市場正在不斷發展。藥品定價分析平台可以分析價格趨勢、支付方行為、市場進入條件、折扣和競爭定位。隨著藥品市場日益複雜，各機構擴大利用分析來制定定價策略和商業計劃。此外，醫療保健相關資料集的日益豐富也使得跨產品、治療領域和區域市場的更深入分析成為可能。

製藥公司利用定價分析來支援新產品上市計畫、打入市場策略、收入預測和產品組合決策。支付方和醫療機構可以使用相關工具來評估支出模式並了解不同治療領域的價格波動。人工智慧和機器學習的應用提高了處理大規模資料集的效率，並能夠識別傳統分析方法難以發現的模式。人們對醫療成本承擔能力和報銷政策日益成長的關注，也促使人們需要更透明、基於證據的定價資訊。

未來前景得益於真實世界醫療保健數據的擴展、先進分析技術的進步以及藥品商業化需求的推動。將定價資訊與報銷、臨床、競爭考察和患者層面洞察相結合的平台能夠提供更廣泛的決策支援能力。資料管治、隱私、合規性和資訊來源的可靠性仍將是重要的考量。隨著醫藥市場日益複雜，預計醫療服務提供者將加大對自動化預測和情境分析的投資。製藥公司、保險公司和醫療機構持續採用分析技術將有助於市場的長期發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面而實用的見解。每份報告都包含幾個關鍵組成部分，旨在讓您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分重點介紹每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區特定分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球藥品定價分析市場：依產品分類

  • 市場分析、洞察與預測
  • 軟體平台
  • 資料和情報資料庫
  • 分析模組
  • API和資料饋送
  • 服務

第5章：全球藥品定價分析市場：依應用領域分類

  • 市場分析、洞察與預測
  • 上市定價
  • 取得和兌換
  • 毛利淨利分析
  • 與付款方簽訂合約
  • 合規分析
  • 其他

第6章：全球藥品定價分析市場：依市場範圍分類

  • 市場分析、洞察與預測
  • 基於雲端的SaaS
  • 現場
  • 混合

第7章 全球藥品定價分析市場：按類型分類

  • 市場分析、洞察與預測
  • 說明分析
  • 診斷分析
  • 預測分析
  • 指示性分析
  • 人工智慧驅動的分析

第8章 全球藥品定價分析市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 製藥公司
  • 生技公司
  • 支付方和藥品福利管理機構
  • 其他

第9章 全球藥品定價分析市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • IQVIA Inc
    • EVERSANA
    • Clarivate Plc
    • GlobalData Plc
    • Model N Inc
    • Wolters Kluwer
    • Merative
    • First Databank Inc
    • IntegriChain
    • MMIT
    • IBM
    • Oracle Corporation
    • SAS Institute Inc
    • Definitive Healthcare
    • Symphony Health
    • Medi-Span
    • Elsevier
    • McKesson Corporation
簡介目錄
Product Code: VMR112119411

The global drug pricing analytics market size is expected to reach USD 4.70 Billion in 2034 from USD 1.63 Billion in 2025, growing at a CAGR of 12.49% during 2026-2034.This market is developing as pharmaceutical companies, healthcare providers, insurers, and governments increasingly require data-driven tools to understand medicine pricing and reimbursement conditions. Drug pricing analytics platforms can analyze pricing trends, payer behavior, market access conditions, discounts, and competitive positioning. Increasing complexity in pharmaceutical markets is encouraging organizations to use analytics for pricing strategy and commercial planning. The growing availability of healthcare datasets is also enabling more sophisticated analysis across products, therapeutic categories, and geographic markets.

Pharmaceutical manufacturers are using pricing analytics to support launch planning, market-access strategies, revenue forecasting, and portfolio decisions. Payers and healthcare organizations can use related tools to assess expenditure patterns and understand price changes across therapeutic areas. Artificial intelligence and machine learning can improve the processing of large datasets and identify patterns that may be difficult to detect through conventional analysis. Increasing attention to healthcare affordability and reimbursement policies is also creating demand for more transparent and evidence-based pricing intelligence.

Future prospects are supported by the expansion of real-world healthcare data, advanced analytics, and pharmaceutical commercialization requirements. Platforms that combine pricing information with reimbursement, clinical, competitive, and patient-level insights can provide broader decision-support capabilities. Data governance, privacy, regulatory compliance, and source reliability will remain important considerations. Providers are likely to invest in automated forecasting and scenario analysis as pharmaceutical markets become more complex. Continued adoption of analytics across manufacturers, payers, and healthcare organizations should support long-term market development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

  • Software Platforms
  • Data & Intelligence Databases
  • Analytics Modules
  • APIs & Data Feeds
  • Services

By Application

  • Launch Pricing
  • Access & Reimbursement
  • Gross-to-Net Analytics
  • Payer Contracting
  • Compliance Analytics
  • Others

By Deployment

  • Cloud-Based/SaaS
  • On-Premises
  • Hybrid

By Type

  • Descriptive Analytics
  • Diagnostic Analytics
  • Predictive Analytics
  • Prescriptive Analytics
  • AI-Enabled Analytics

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Payers & PBMs
  • Others

COMPANIES PROFILED

  • IQVIA Inc., EVERSANA, Clarivate Plc, GlobalData Plc, Model N Inc., Wolters Kluwer, Merative, First Databank Inc., IntegriChain, MMIT, IBM, Oracle Corporation, SAS Institute Inc., Definitive Healthcare, Symphony Health, Medi-Span, Elsevier, McKesson Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DRUG PRICING ANALYTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Software Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Data & Intelligence Databases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Analytics Modules Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. APIs & Data Feeds Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DRUG PRICING ANALYTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Launch Pricing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Access & Reimbursement Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Gross-to-Net Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Payer Contracting Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Compliance Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DRUG PRICING ANALYTICS MARKET: BY DEPLOYMENT 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Deployment
  • 6.2. Cloud-Based/SaaS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. On-Premises Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Hybrid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DRUG PRICING ANALYTICS MARKET: BY TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Type
  • 7.2. Descriptive Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Diagnostic Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Predictive Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Prescriptive Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. AI-Enabled Analytics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DRUG PRICING ANALYTICS MARKET: BY END USER 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End User
  • 8.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Payers & PBMs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL DRUG PRICING ANALYTICS MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Product
    • 9.2.2 By Application
    • 9.2.3 By Deployment
    • 9.2.4 By Type
    • 9.2.5 By End User
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Product
    • 9.3.2 By Application
    • 9.3.3 By Deployment
    • 9.3.4 By Type
    • 9.3.5 By End User
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Spain
    • 9.3.11 Russia
    • 9.3.12 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Product
    • 9.4.2 By Application
    • 9.4.3 By Deployment
    • 9.4.4 By Type
    • 9.4.5 By End User
    • 9.4.6 China
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 India
    • 9.4.10 Australia
    • 9.4.11 South East Asia
    • 9.4.12 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Product
    • 9.5.2 By Application
    • 9.5.3 By Deployment
    • 9.5.4 By Type
    • 9.5.5 By End User
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Product
    • 9.6.2 By Application
    • 9.6.3 By Deployment
    • 9.6.4 By Type
    • 9.6.5 By End User
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL DRUG PRICING ANALYTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 IQVIA Inc
    • 11.2.2 EVERSANA
    • 11.2.3 Clarivate Plc
    • 11.2.4 GlobalData Plc
    • 11.2.5 Model N Inc
    • 11.2.6 Wolters Kluwer
    • 11.2.7 Merative
    • 11.2.8 First Databank Inc
    • 11.2.9 IntegriChain
    • 11.2.10 MMIT
    • 11.2.11 IBM
    • 11.2.12 Oracle Corporation
    • 11.2.13 SAS Institute Inc
    • 11.2.14 Definitive Healthcare
    • 11.2.15 Symphony Health
    • 11.2.16 Medi-Span
    • 11.2.17 Elsevier
    • 11.2.18 McKesson Corporation